Editas Medicine, Inc.
EDITNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for EDIT. That does not mean none is planned.
Get an email about EDIT's next catalysts
Track Editas Medicine (EDIT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
EDIT Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.21 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
WebsiteNo drugs found in this phase.
Frequently asked questions
When is Editas Medicine, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Editas Medicine, Inc. (EDIT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track EDIT biotech catalysts?→
Add EDIT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Editas Medicine, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.